Real-time insights for smart engagement with CGM (rise-CGM)

The National Institute of Diabetes and Digestive and Kidney Diseases awarded Healthpartners Institute $314,000 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and test RISE-CGM (Real-Time Insights for Smart Engagement with CGM), a digital behavior change intervention targeting type 2 diabetes self-management.

RISE-CGM is a 28-week scalable intervention (16 weeks active, 12 weeks maintenance) that delivers evidence-based nutrition and lifestyle education to people with type 2 diabetes using real-time continuous glucose monitoring data and text messaging. The intervention applies self-determination theory to generate personalized, just-in-time messages encouraging real-time learning and behavior change, and incorporates systematic retrospective glucose data reviews. The project uses the Obesity-Related Behavioral Intervention Trials (ORBIT) framework to conduct Phase-level behavioral intervention research.

Performance of performance is Bloomington, Minnesota. The project runs from July 15, 2026, to May 31, 2029. Healthpartners Institute is a non-profit research organization and subsidiary of Healthpartners, Inc., operating as both a prime recipient and sub-recipient on federal grants and contracts across NIH, CDC, and other public health agencies, with a research portfolio anchored in clinical epidemiology, vaccine safety surveillance, real-world evidence, and implementation science.

Abstract

Nearly 35 million americans have type 2 diabetes (T2D), a chronic condition characterized by hyperglycemia (high blood glucose) that requires continual engagement in healthy lifestyle behaviors, such as making optimal food and lifestyle choices. Currently, only about 20% of people globally with T2D are meeting established glycemic targets-which are critical for reducing diabetes-related complications-and which suggests that innovative strategies are urgently needed to support and empower individuals in their T2D self-management. Recent improvements in continuous glucose monitoring (CGM) allow people with T2D to see their glucose in real-time and as aggregated trends over time (retrospective data) without repeated finger sticks or lab draws. This consistent access to biofeedback from the CGM has significant potential to help people with T2D learn how foods and other lifestyle behaviors impact their glucose, which could lead to sustainable behavior changes and improved glycemia. Relatedly, digital behavior change interventions (dbcis) have been shown to lead to small, but significant, improvements in glycemic and diabetes-related outcomes compared to usual care in people with T2D. Thus, we have designed a novel intervention, rise-CGM-or real-time insights for smart engagement with CGM-a scalable 28-week dbci (16-week active intervention and 12-week maintenance) that delivers evidence-based nutrition and lifestyle-focused CGM education and support specifically for people with T2D. Rise-CGM is based on self-determination theory and uses real-time CGM data and text messaging to deliver personalized, just-in-time messages that encourage real-time learning and decision-making about behaviors for improved glucose management. Rise-CGM also incorporates systematic retrospective CGM data reviews. Using the obesity-related behavioral intervention trials (orbit) framework, we propose to conduct a phase IIB randomized feasibility trial at healthpartners institute's international diabetes center, where 60 participants with T2D will be randomized 1:1 to use either the rise-CGM intervention or CGM-only for 28 weeks. The proposed trial will test three aims. Aim 1: examine the acceptability of the rise-CGM technological framework. Aim 2: determine the feasibility of delivering the rise-CGM intervention and the research study design. Aim 3: determine whether rise-CGM impacts the targeted mechanisms of behavior change in the expected directions and to a greater extent than the CGM-only arm. Aim 4 (exploratory): examine the plausibility that rise-CGM impacts behavior changes and glycemic metrics (i.e., time in range and A1C). This research is a critical first step before conducting a fully powered randomized controlled trial of the rise-CGM intervention. The proposed research will provide data-driven insights to refine rise-CGM and design and implement future rise-CGM trials. Significance: the long-term goal of this research line is to design a scalable, evidence-based approach that enhances T2D self-management and leads to improved glycemia, which could ultimately reduce diabetes-related complications and economic burden.